SAN FRANCISCO--(BUSINESS WIRE)--Osmind, the public benefit corporation helping clinicians and researchers advance new life-saving mental health treatments, today announced a $40 million Series B ...

SAN FRANCISCO--(BUSINESS WIRE)--Osmind, a healthcare technology company building the first digital infrastructure for neuropsychiatry, closed $15 million in Series A funding to further develop and ...

Tasman Therapeutics today announced a multi-year strategic partnership with Osmind, the market leader in technology and real-world evidence for psychiatry, to support its R-107 Ketamine program. The ...

San Francisco-based Osmind announced today that its electronic health record system for mental health clinicians has integrated Zoom virtual visits within its technology platform as part of the ...

Osmind presented a retrospective comparative study of de-identified electronic health record data in a sample of 8,224 patients with treatment resistant depression treated with IV ketamine and 1,830 ...

Jimmy Qian and Lucia Huang, the co-founders of Osmind, a new clinical practice management and data analysis platform for mental health providers focusing on cutting edge psychedelic treatments, met at ...

This article was originally published on Microdose Psychedelic Insights and appears here with permission. This week’s Psychedelic Guide is Lucia Huang, Co-founder and CEO of Osmind. Osmind is ...

US digital health firm Osmind – which had developed an electronic health record (EHR) system for patients with mental illness – has added to its finances with a $40 million Series B financing. The San ...

Funding will support expansion of Osmind’s next-generation neuropsychiatry software platform and team growth SAN FRANCISCO–(BUSINESS WIRE)–July 1, 2021– Osmind, a healthcare technology company ...

Tasman Therapeutics enters partnership with Osmind to advance R-107 for depressive disorders: San Francisco Thursday, August 13, 2026, 17:00 Hrs [IST] Tasman Therapeutics, a clini ...